• Hansoh Pharma signed an exclusive global license with Avere for oral IL-23 receptor antagonist HS-20118, excluding mainland China, Hong Kong, Macau, Taiwan.
• Deal terms include USD 120 million upfront payments, up to USD 2.18 billion in development and sales milestones, royalties from mid-single to low-double digits.
• Hansoh also made a minority investment in Avere via subscription of convertible notes tied to a merger closing.
• Avere agreed to merge with Nasdaq-listed NextCure in an all-stock transaction, expected in H2 2026; combined company to trade as AVRX.
• Hansoh expects to own more than 30% but less than 40% of the combined entity on a fully diluted basis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.